Countervail Corporation

News

Countervail Corporation presents significant results of i.m. dosed AverTox (galantamine) for improved survival from exposure to lethal levels of soman at the CounterACT Symposium held in Denver Colorado.

Data funded by an SBIR grant was presented at the annual CounterACT meeting on the use of AverTox (galantamine) dosed by intramuscular injection in advance of an exposure to lethal levels of soman in guinea pigs. These data demonstrated that the use of galantamine significantly improved the survival outcomes and provided neuroprotection over the use of conventional standard care antidotes alone.